Raymond Anton to Follow-Up Studies
This is a "connection" page, showing publications Raymond Anton has written about Follow-Up Studies.
Connection Strength
0.713
-
Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
Score: 0.107
-
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
Score: 0.093
-
Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. Alcohol Clin Exp Res. 2017 May; 41(5):1054-1062.
Score: 0.093
-
Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
Score: 0.091
-
Biomarkers as aids to identification of relapse in alcoholic patients. Recent Dev Alcohol. 2003; 16:25-38.
Score: 0.035
-
Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 08 01; 201:16-22.
Score: 0.027
-
Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug Alcohol Depend. 2019 04 01; 197:228-235.
Score: 0.026
-
Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. Alcohol Clin Exp Res. 2018 11; 42(11):2256-2265.
Score: 0.026
-
Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017 06; 4(6):469-476.
Score: 0.023
-
Proposed recommendations for research on biochemical markers for problematic drinking. Alcohol Clin Exp Res. 1997 Apr; 21(2):244-7.
Score: 0.023
-
The use of carbohydrate deficient transferrin as an indicator of alcohol consumption during treatment and follow-up. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):54A-56A.
Score: 0.023
-
Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res. 1996 Aug; 20(5):841-6.
Score: 0.022
-
Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
Score: 0.022
-
Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
Score: 0.020
-
Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2014 Jan; 19(1):41-9.
Score: 0.018
-
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
Score: 0.017
-
Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol. 2012 Nov-Dec; 47(6):683-7.
Score: 0.017
-
Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009 Mar; 70(2):186-96.
Score: 0.013
-
A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. 2000 Aug 01; 60(2):161-8.
Score: 0.007
-
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
Score: 0.005
-
A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992 Dec; 16(6):1007-13.
Score: 0.004